Table 4 Clinical and laboratory data by PD- and GS-detected entheseal abnormalities

Age^a

52 (23.5-58.3)

38 (29–45)

0.707

40 (28–56)

33.5 (24.5-38.5)

0.155

40 (28–56)

33.5 (24.5-38.5)

0.102

BMI^a

22.59 (19.9-24.6)

23.24 (19.9-25.9)

0.608

23.4 (20.9-26.4)

21.9 (19.7-24.4)

0.297

23.24 (20.9-26.4)

21.87 (19.7-24.4)

0.297

Disease duration^a

6 (2.3-9.5)

7 (4.5-12)

0.695

7 (4–12)

6.5 (4.5-10)

0.724

7 (4–12)

6.5 (4.5-10)

0.972

Disease flare^a

2.50 (2–3.75)

3 (2–5)

0.009*

4 (2–5)

2 (1.75-53)

0.204

4 (2–5)

2 (1.75-3)

0.295

Active disease^b

21

79

0.883

0

100

0.53

9.1

91.9

0.721

ESR^a

8.5 (5.3-9.8)

10 (6–17.5)

0.224

8 (5–11)

14.5 (10–29)

0.116

8 (5–11)

14.5 (10–29)

0.196

CRP^a

0.35 (0.19-075)

0.19 (0.09-0.8)

0.044*

0.19 (0.1-0.61)

0.4 (0.1-1.3)

0.116

0.19 (0.1-0.6)

0.4 (0.1-1.35)

0.796

ASCA^b

15.8

84.2

0.127

78.9

21.1

0.991

30

70

0.822

pANCA^b

21.4

78.6

0.476

57.1

42.9

0.022*

16

84

0.011*

Steroids^b

14.3

85.7

0.271

14.2

85.8

0.835

9.4

90.6

0.909

Anti-TNFα^b

40

60

0.356

92

8

0.14

37.5

62.5

0.05

AZA^b

9

91

0.005*

68.1

31.9

0.030*

23.4

76.6

0.014*

5 ASA^b

40

60

0.745

41.2

58.8

0.745

39.1

60.0

0.727